Home / Intelligence / Webinars / Navigating the Early Asset Evaluation Journey with Confidence
Available On Demand
There is no room for missteps along the journey to evaluate the viability of assets in early stages of development. When making go/no go decisions, many critical questions must be answered across the early asset lifecycle.
Join a team of cross-functional experts from Trinity Life Sciences for a lively panel discussion on how to approach early commercial assessment with insight from various perspectives. The team will share real-life examples highlighting what life sciences companies need to be thinking about and common pitfalls they must avoid to navigate the early asset evaluation journey with confidence.
Key Webinar Topics
- What are the critical questions along the asset evaluation journey?
- How do you identify which indication to prioritize to maximize value?
- How do you bring various internal stakeholders to the table?
- How can you drive smart, lean insights and analytics for a new asset?
- When and how do you typically consider regionality in the process?
Featuring
Bami Oshinowo
Partner, Value, Access & Pricing
& London Office Lead
Julie Fleming
Partner
Lauren Peters Radeck
Partner
Monique Marsh
Associate Director &
Co-Head of Trinity Marketing Communications Insights
Complete the form below to view the on-demand webinar.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
White Papers
Predicting Winners: AI-Powered Portfolio Management
Can artificial intelligence and machine learning (AIML) be used to support portfolio decision-making across the life sciences industry? In this installment of our Industry Impact Series, we find that not only can the latest AIML techniques identify the drivers of success and failure in commercialization, but Trinity Life Sciences’ AI algorithm accurately predicts revenue outcomes for […]
Read More
Webinars
Trinity Annual Drug Index
Available On Demand
White Paper & On-demand Webinar: This report, the seventh in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the performance of novel drugs approved by the FDA in 2021, scoring each […]
Watch Now
Briefs
The “Molecular Optimizer” Archetype: A Strategy for First-Launch Companies to Streamline Their Path to Market
The “molecular optimizer” archetype is a strategy utilized by first-launch companies to optimize existing molecules when developing their first product. Companies using this approach tend to be small and emerging biotech firms that are seeking a foothold to enter the market. The primary benefit of this approach is that the method offers a higher probability […]
Read More